Macleods Pharma USA, Inc. initiated a Class II drug recall for Levothyroxine Sodium Tablets USP 150 mcg, 1000 tablet bottles, distributed nationwide. The reason for recall is subpotent drug - the medication may contain less than the required active pharmaceutical ingredient. This Class II classification indicates the subpotent product may cause temporary or medically reversible adverse health consequences, or remote possibility of serious adverse effects if the medication does not provide adequate thyroid hormone replacement.

Pharmaceutical distributors and healthcare providers should immediately identify and quarantine any remaining stock of the affected Levothyroxine 150 mcg product. Pharmacies should check their inventory against recall notices and notify patients who may have received this medication. Patients currently taking this product should contact their healthcare provider to discuss alternative thyroid hormone replacement therapy and report any adverse effects. The recall is ongoing and additional lot-specific information should be monitored through FDA communications.